- Home
- RANI
RANI
Rani Therapeutics Holdings Inc.
as 04-18-2025 1:42pm EST
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $11.33 | AVG Volume (30 days): | 184.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $8.75 | Next Earning Date: | 05-05-2025 |
| Revenue: | $1,028,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 24705.45% | Revenue Growth (next year): | -95.65% |
Latest Rani Therapeutics Holdings Inc. News
RANI Breaking Stock News: Dive into RANI Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
18 days ago
RANI: 2024 Financial Results
Thomson Reuters StreetEvents
18 days ago
Q4 2024 Rani Therapeutics Holdings Inc Earnings Call
GuruFocus.com
18 days ago
Rani Therapeutics Holdings Inc (RANI) Q4 2024 Earnings Call Highlights: Navigating Financial ...
GlobeNewswire
19 days ago
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
GlobeNewswire
24 days ago
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
GlobeNewswire
25 days ago
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Zacks Small Cap Research
2 months ago
RANI: Impressive Bioavailability for RT-116
Simply Wall St.
2 months ago
Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) largest shareholders are individual investors who were rewarded as market cap surged US$11m last week
Compare RANI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RANI Rani Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.